MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Gross proceedsreceived from the sale of...$10,480K Gross proceedsreceived from the...$20K Net cash provided byfinancing activities$9,559K Canceled cashflow$941K Net increase in cash$7,293K Canceled cashflow$2,266K Fees related topublic offering$939K Fee related to theexercise of prefunded...$2K Goodwill Impairment Loss$2,000K Accounts payable andaccrued expenses$759K Due from relatedparty-$750K Stock-based compensation$309K Issuance of common stockto consultant for...$96K Other liabilities$93K Amortization of right-of-useasset$78K Depreciation andamortization$8K Net increase in cash$7,293K Net cash used inoperating activities-$2,264K Net cash used ininvesting activities-$2K Canceled cashflow$4,093K Net Income Loss-$5,500K Purchase of property andequipment$2K Due to related party-$500K Prepaid expenses andother current assets$320K Operating lease liability-$75K
Cash Flow

Ernexa Therapeutics Inc. (ERNAW)

Ernexa Therapeutics Inc. (ERNAW)

source: myfinsight.com